Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

被引:46
作者
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2001.19.12.3025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). Patients and Methods: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. Results: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival far those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. Conclusion: RT-PCR for PSA predicts survival duration in a population of men with HRPC. J Clin Oncol 19:3025-3028. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3025 / 3028
页数:4
相关论文
共 13 条
[1]  
CARROLL PR, 2001, PRINCIPLES PRACTICES, P1418
[2]  
COX DR, 1974, J ROY STAT SOC B, V74, P187
[3]  
De la Taille A, 1999, INT J CANCER, V84, P360, DOI 10.1002/(SICI)1097-0215(19990820)84:4<360::AID-IJC5>3.0.CO
[4]  
2-E
[5]   Prognostic indicators in hormone refractory prostate cancer [J].
George, DJ ;
Kantoff, PW .
UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) :303-+
[6]   Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma [J].
Ghossein, RA ;
Juan, RS ;
Scher, HI ;
Seiden, M ;
Zhang, ZF ;
Sun, M ;
Chang, G ;
Berlane, K ;
Krithivas, K ;
Kantoff, PW .
UROLOGY, 1997, 50 (01) :100-105
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]  
KATZ AE, 1995, CANCER-AM CANCER SOC, V75, P1642, DOI 10.1002/1097-0142(19950401)75:7<1642::AID-CNCR2820750714>3.0.CO
[9]  
2-1
[10]   Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence [J].
Mejean, A ;
Vona, G ;
Nalpas, B ;
Damotte, D ;
Brousse, N ;
Chretien, Y ;
Dufour, B ;
Lacour, B ;
Bréchot, C ;
Paterlini-Bréchot, P .
JOURNAL OF UROLOGY, 2000, 163 (06) :2022-2029